| US 7,560,253 B1 | ||
| HLS-5 tumor suppressor factor | ||
| Svend Peter Klinken, Kensington (Australia); Jean-Philippe Lalonde, Subiaco (Australia); and James Howard Williams, Mosman Park (Australia) | ||
| Assigned to The University of Western Australia, Nedlands (Australia) | ||
| Appl. No. 10/130,971 PCT Filed Nov. 24, 2000, PCT No. PCT/AU00/01439 § 371(c)(1), (2), (4) Date Sep. 26, 2002, PCT Pub. No. WO01/38374, PCT Pub. Date May 31, 2001. |
||
| Claims priority of application No. PQ4216 (AU), filed on Nov. 24, 1999. | ||
| Int. Cl. C12P 19/34 (2006.01); C12Q 1/68 (2006.01) | ||
| U.S. Cl. 435—91.2 [435/6] | 11 Claims |
| 1. A method for detecting the level of expression of a hemopoietic linkage switch-5 (HLS-5) polynucleotide in a biological
sample from a suspected or known cancer patient comprising:
(a) providing a biological sample from the patient comprising a nucleic acid;
(b) contacting, under stringent hybridizing conditions, the biological sample with a polynucleotide probe or primer capable
of hybridizing to an HLS-5 polynucleotide selected from the group consisting of:
(i) polynucleotides comprising the nucleotide sequence set out in SEQ ID NO:1 or SEQ ID NO:3;
(ii) polynucleotides fully complementary to the polynucleotides of (i); and
(iii) polynucleotides encoding an HLS-5 polypeptide comprising at least 95% sequence identity with the sequence set out in
SEQ ID NO:2 or SEQ ID NO:4;
(c) determining a total amount of duplex formed in the sample between the probe or primer and HLS-5 polynucleotide selected
from the group consisting of (b)(i), (b)(ii), and (b)(iii); and
(d) comparing the total amount of duplex in step (c) to a control or standard comprising a known amount of an HLS-5 polynucleotide
found in a comparable biological sample taken from a non-cancer patient.
|